Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments (Lizette Chapman/Bloomberg)
Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments (Lizette Chapman/Bloomberg) https://ift.tt/3qCdP9l
Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments — Palantir Technologies Inc. won a deal with the U.S. Food and Drug Administration to help power drug reviews and inspections …
0 Response to "Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments (Lizette Chapman/Bloomberg)"
Post a Comment
THANK YOU